Johnson & Johnson announced a proposed Plan of Reorganization for the resolution of ovarian cancer claims, resulting in a charge of $2.7 billion and a reduction in net earnings and EPS for the first quarter of 2024.
AI Assistant
JOHNSON & JOHNSON
2024
8 K
Find Answers
Ask about any part of the document to get insights, explanations, or key details.